相似文献
1
Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex.
Emerg Microbes Infect. 2023 Dec;12(1):2148563. doi: 10.1080/22221751.2022.2148563.
2
Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex.
Ann Neurol. 1982 Apr;11(4):359-64. doi: 10.1002/ana.410110407.
3
Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study.
J Child Neurol. 2003 Dec;18(12):819-27. doi: 10.1177/088307380301801201.
4
The influence of inosiplex treatment on the neurological disability of patients with subacute sclerosing panencephalitis.
J Pediatr. 1982 Aug;101(2):288-93. doi: 10.1016/s0022-3476(82)80143-1.
5
The effect of inosiplex on the survival of subacute sclerosing panencephalitis.
Neurology. 1983 Aug;33(8):1053-5. doi: 10.1212/wnl.33.8.1053.
6
Treatment of subacute sclerosing panencephalitis with interferon-alpha, ribavirin, and inosiplex.
J Child Neurol. 2002 Sep;17(9):703-5. doi: 10.1177/088307380201700911.
7
[Therapy and prognosis in subacute sclerosing panencephalitis].
Nihon Rinsho. 2007 Aug;65(8):1483-6.
8
[The effect of inosiplex in subacute sclerosing panencephalitis (SSPE)].
No To Hattatsu. 1984 Jul;16(4):262-70.
9
Treatment of subacute sclerosing panencephalitis: an overview.
Drug Intell Clin Pharm. 1984 May;18(5):375-81. doi: 10.1177/106002808401800503.
10
Inosiplex therapy in subacute sclerosing panencephalitis. A multicentre, non-randomised study in 98 patients.
Lancet. 1982 May 8;1(8280):1034-7. doi: 10.1016/s0140-6736(82)92097-9.
本文引用的文献
1
Subacute Sclerosing Panencephalitis in Children: The Archetype of Non-Vaccination.
Viruses. 2022 Mar 31;14(4):733. doi: 10.3390/v14040733.
2
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis.
Molecules. 2021 Jan 15;26(2):427. doi: 10.3390/molecules26020427.
3
Progress Toward Measles Elimination - Eastern Mediterranean Region, 2013-2019.
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):439-445. doi: 10.15585/mmwr.mm6915a2.
4
Neurological Complications of Measles (Rubeola).
Curr Neurol Neurosci Rep. 2020 Feb 7;20(2):2. doi: 10.1007/s11910-020-1023-y.
5
Measles Encephalitis: Towards New Therapeutics.
Viruses. 2019 Nov 2;11(11):1017. doi: 10.3390/v11111017.
6
Subacute sclerosing panencephalitis.
Rev Med Virol. 2019 Sep;29(5):e2058. doi: 10.1002/rmv.2058. Epub 2019 Jun 24.
7
Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.
Adv Ther. 2019 Aug;36(8):1878-1905. doi: 10.1007/s12325-019-00995-6. Epub 2019 Jun 5.
8
Measles: a disease often forgotten but not gone.
Hong Kong Med J. 2018 Oct;24(5):512-520. doi: 10.12809/hkmj187470.
9
Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated.
Clin Infect Dis. 2017 Jul 15;65(2):226-232. doi: 10.1093/cid/cix302.
10
Subacute sclerosing panencephalitis: an update.
Dev Med Child Neurol. 2010 Oct;52(10):901-7. doi: 10.1111/j.1469-8749.2010.03717.x. Epub 2010 Jun 15.
Zotero 插件
